|
1. BIOLOGIE
|
|
|
|
The structure of a T-cell mechanosensor [Nature]
|
|
|
|
|
|
T-cell receptors orchestrate immune-system responses against infection and cancer. A structure of an entire T-cell receptor complex clarifies its assembly and signalling, and sheds light on its dynamic ligand recognition.
|
|
|
|
|
|
|
1.5 PRIX LASKER
|
|
|
Celebrating the 2019 Lasker Awards: A Cell Collection [Cell]
|
|
|
|
|
|
In this year’s collection, which includes opening remarks from Joseph L. Goldstein, Chair of the Albert Lasker Medical Research Awards jury, we present features on the scientific achievements underpinning the awards, and we hear from the winners themselves as they recount their unique paths to scientific and medical progress.
|
|
|
|
|
|
|
|
The Team that Just Wouldn’t Quit and a New Paradigm in Cancer Drug Discovery [Cell]
|
|
|
|
|
|
Receiving the Lasker award for Clinical Medical Research is a staggering event. Perhaps equally staggering is the fact that as many as 2 million women worldwide have now been treated with Herceptin (trastuzumab), many of whom benefited from the treatment. This accomplishment is wonderfully rewarding for everyone who has been involved.
|
|
|
|
|
|
|
|
|
Biomarker-Driven Drug Discovery in Cancer—Trastuzumab Development [JAMA]
|
|
|
|
|
|
The 2019 Lasker-DeBakey Clinical Medical Research Award has been presented to H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich for the invention of trastuzumab, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer.
|
|
|
|
|
|
|
Moving from Cancer Genetics to Therapy [Cell]
|
|
|
|
|
|
Cell editor Lara Szewczak spoke with Dennis, the recipient of the 2019 Lasker-DeBakey Clinical Medical Research Award, to discuss the research leading to trastuzumab and his views on how current progress in treating cancers may impact the US health care system.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
|
5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.13 WCLC
|
|
|
|
5.13.1 WCLC - IMMUNOTHÉRAPIES
|
|
|
|
|
|
|
|
|
|
5.13.1.1 WCLC - BIOMARQUEURS
|
|
|
|
|
5.13.4 WCLC - DIVERS
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.6 ESMO
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
|
Rise of the platforms [Nature Physics]
|
|
|
|
|
|
Facebook and Google connect advertisers, businesses and everyday users. Uber connects riders and drivers. And the online platforms of major journals connect scientists that may variously act as authors, readers and reviewers.
|
|
|
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|